Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas



Status:Archived
Conditions:Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2008
End Date:May 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas


Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in
Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or
Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of
plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid
tumors or lymphomas.


Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in
Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or
Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD), the
pharmacokinetics (PK) of these combinations, drug-drug PK interactions, preliminary
information on the clinical antitumor activity of these combinations in solid tumors,perform
a preliminary pharmacogenomic (PGx) study of potential biomarkers of sensitivity/resistance
to these drugs combinations and of prognostic markers of the treatment outcome in tumor
tissue sample.


We found this trial at
1
site
The Cancer Institute of New Jersey (CINJ)
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials